Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL
CVAY736J12101
Phase 1 other active
Quick answer
Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL for Relapsed/refractory Non Hodgkin Lymphoma is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Relapsed/refractory Non Hodgkin Lymphoma
- Phase
- Phase 1
- Modality
- other
- Status
- active